EFFECT OF MELATONIN SUPPLEMENTATION AND TYPE 2 DIABETES MELLITUS (T2DM) : A SYSTEMATIC REVIEW

Authors

  • Derrick Santo Vincentius General Hospital, Singkawang City, West Borneo, Indonesia
  • Hendry Halim Departement of Internal Medicine, Santo Vincentius General Hospital, Singkawang City, West Borneo, Indonesia

DOI:

https://doi.org/10.53555/nnmhs.v8i12.1468

Keywords:

Diabetes Mellitus, Hyperglycemia, Melatonin, Oxidative Stress

Abstract

Pineal gland secretion of the endogenous indole amine known as melatonin is regulated by the hypothalamus. The 24-hour cycle of circadian rhythms is partially responsible for the timing of physiologic processes. Research conducted in the past has demonstrated that melatonin possesses a variety of advantageous properties, such as activities that limit the responses of adrenocorticotropic hormones and good effects that have an effect on metabolic profiles. In addition, there has been research carried out on animals, in addition to certain human trials that were not randomized, which have suggested that the use of melatonin may have a positive influence on improving glycemic control, insulin resistance, hypertension, and dyslipidemia. These studies were carried out in conjunction with one another. In studies conducted on both humans and animals, melatonin was discovered to have a beneficial effect on the regulation of blood glucose levels. The expression of the glucose transporter type 4 (GLUT4) gene is reduced in mice that have had their pineal glands surgically removed, which leads to glucose intolerance and insulin resistance. Melatonin treatment is effective in reducing the severity of these symptoms. Melatonin's anti-oxidative activity effectively lowers oxidative stress, which is a significant contributor to the progression of a wide variety of problems that can arise from diseases such as diabetes.

 

References

Association AD. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2014;37(Supplement_1):S81–90.

International Diabetes Federation. Diabetes. Brussels: IDF; 2017.

Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract. 2010;87(1):4–14.

Du W, Peng S-M, Liu Z, Shi L, Tan L-F, Zou X-Q. Hypoglycemic effect of the water extract of Pu-erh tea. J Agric Food Chem. 2012;60(40):10126–32.

Sivertsen B, Lallukka T, Petrie KJ, Steingrímsdóttir ÓA, Stubhaug A, Nielsen CS. Sleep and pain sensitivity in adults. Pain. Agustus 2015;156(8):1433–9.

Szewczyk PB, Dziuba AM, Poniewierka E. Melatonin–metabolism and the role of pineal hormone. Piel?gniarstwo i Zdr Publiczne Nurs Public Heal. 2018;8(2):135–9.

Frese T, Bach AG, Mühlbauer E, Pönicke K, Brömme H-J, Welp A, et al. Pineal melatonin synthesis is decreased in type 2 diabetic Goto–Kakizaki rats. Life Sci. 2009;85(13–14):526–33.

Ozkanlar S, Kara A, Sengul E, Simsek N, Karadeniz A, Kurt N. Melatonin modulates the immune system response and inflammation in diabetic rats experimentally-induced by alloxan. Horm Metab Res. 2016;48(02):137–44.

Ríos?Lugo MJ, Cano P, Jiménez?Ortega V, Fernández?Mateos MP, Scacchi PA, Cardinali DP, et al. Melatonin effect on plasma adiponectin, leptin, insulin, glucose, triglycerides and cholesterol in normal and high fat–fed rats. J Pineal Res. 2010;49(4):342–8.

Pevet P, Challet E. Melatonin: both master clock output and internal time-giver in the circadian clocks network. J Physiol. 2011;105(4–6):170–82.

Bazyar H, Zare Javid A, Bavi Behbahani H, Moradi F, Moradi Poode B, Amiri P. Consumption of melatonin supplement improves cardiovascular disease risk factors and anthropometric indices in type 2 diabetes mellitus patients: a double-blind, randomized, placebo-controlled trial. Trials. Maret 2021;22(1):231.

Kandemir YB, Tosun V, Korucuk N, Bozdemir MN. Melatonin protects against streptozotocin-induced diabetic cardiomyopathy by the phosphorylation of vascular endothelial growth factor-A (VEGF-A). Cell Mol Biol. 2018;64(14):47–52.

Rezvanfar MR, Heshmati G, Chehrei A, Haghverdi F, Rafiee F, Rezvanfar F. Effect of bedtime melatonin consumption on diabetes control and lipid profile. Int J Diabetes Dev Ctries. 2017;37(1):74–7.

Boga JA, Caballero B, Potes Y, Perez?Martinez Z, Reiter RJ, Vega?Naredo I, et al. Therapeutic potential of melatonin related to its role as an autophagy regulator: A review. J Pineal Res. 2019;66(1):e12534.

She Q, Han Z, Liang S, Xu W, Li X, Zhao Y, et al. Impacts of circadian rhythm and melatonin on the specific activities of immune and antioxidant enzymes of the Chinese mitten crab (Eriocheir sinensis). Fish Shellfish Immunol. 2019;89:345–53.

Pourhanifeh MH, Hosseinzadeh A, Dehdashtian E, Hemati K, Mehrzadi S. Melatonin: new insights on its therapeutic properties in diabetic complications. Diabetol Metab Syndr [Internet]. 2020;12(1):30. Tersedia pada: https://doi.org/10.1186/s13098-020-00537-z

Zhang C, Zhang Q, Pang Y, Song X, Zhou N, Wang J, et al. The protective effects of melatonin on oxidative damage and the immune system of the Chinese mitten crab (Eriocheir sinensis) exposed to deltamethrin. Sci Total Environ. 2019;653:1426–34.

Jockers R, Delagrange P, Dubocovich ML, Markus RP, Renault N, Tosini G, et al. Update on melatonin receptors: IUPHAR Review 20. Br J Pharmacol. 2016;173(18):2702–25.

Rodrigues SC, Pantaleão L, Lellis?Santos C, Veras K, Amaral F, Anhê G, et al. Increased corticosterone levels contribute to glucose intolerance induced by the absence of melatonin. Wiley Online Library; 2013.

Sun H, Wang X, Chen J, Gusdon AM, Song K, Li L, et al. Melatonin Treatment Improves Insulin Resistance and Pigmentation in Obese Patients with Acanthosis Nigricans. Int J Endocrinol. 2018;2018:2304746.

de Oliveira AC, Andreotti S, Sertie RAL, Campana AB, de Proença ARG, Vasconcelos RP, et al. Combined treatment with melatonin and insulin improves glycemic control, white adipose tissue metabolism and reproductive axis of diabetic male rats. Life Sci. 2018;199:158–66.

Sartori C, Dessen P, Mathieu C, Monney A, Bloch J, Nicod P, et al. Melatonin improves glucose homeostasis and endothelial vascular function in high-fat diet-fed insulin-resistant mice. Endocrinology. 2009;150(12):5311–7.

Garfinkel D, Zorin M, Wainstein J, Matas Z, Laudon M, Zisapel N. Efficacy and safety of prolonged-release melatonin in insomnia patients with diabetes: a randomized, double-blind, crossover study. Diabetes, Metab Syndr Obes targets Ther. 2011;4:307.

Doosti-Irani A, Ostadmohammadi V, Mirhosseini N, Mansournia MA, Reiter RJ, Kashanian M, et al. The effects of melatonin supplementation on glycemic control: a systematic review and meta-analysis of randomized controlled trials. Horm Metab Res. 2018;50(11):783–90.

McMullan CJ, Schernhammer ES, Rimm EB, Hu FB, Forman JP. Melatonin Secretion and the Incidence of Type 2 Diabetes. JAMA [Internet]. 3 April 2013;309(13):1388–96. Tersedia pada: https://doi.org/10.1001/jama.2013.2710

Downloads

Published

2022-12-10

How to Cite

Derrick, & Halim, H. . (2022). EFFECT OF MELATONIN SUPPLEMENTATION AND TYPE 2 DIABETES MELLITUS (T2DM) : A SYSTEMATIC REVIEW. Journal of Advanced Research in Medical and Health Science (ISSN 2208-2425), 8(12), 49-55. https://doi.org/10.53555/nnmhs.v8i12.1468